NCT04105335View on ClinicalTrials.gov

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

January 25, 2025

Study Completion Date

January 25, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

MTL-CEBPA

Intravenous administration

DRUG

Pembrolizumab

Intravenous administration

Trial Locations (3)

SE1 9RT

Guys and St Thomas NHS Foundation Trust, London

W12 0HS

Imperial College Healthcare NHS Trust, London

NE7 7DN

Freeman Hospital, Newcastle Upn Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors

lead

Mina Alpha Limited

INDUSTRY

NCT04105335 - A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) | Biotech Hunter | Biotech Hunter